SF
CORT icon

Summit Financial’s Corcept Therapeutics CORT Stock Holding History

Summit Financial’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$333K Buy
+3,825
New +$231K ﹤0.01% 1267
2026
Q1 		– Sell
-6,508
Closed -$226K – 1413
2025
Q4 		$226K Buy
6,508
+3,000
+86% +$236K ﹤0.01% 1191
2025
Q3 		$292K Buy
3,508
+3
+0.1% +$217 ﹤0.01% 1070
2025
Q2 		$257K Buy
3,505
+505
+17% +$36.6K 0.01% 726
2025
Q1 		$343K Buy
+3,000
New +$183K 0.01% 585

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Summit Financial's CORT Position: Q2 2026 in Review

Summit Financial opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 3,825 shares worth $333K. The stake represents ﹤0.01% of the portfolio and ranks #1267 among its holdings. This is a return to the name: Summit Financial previously reported a position in CORT as recently as Q4 2025.

Summit Financial first reported a position in CORT in Q1 2025 and has held it in 5 quarters since. The position peaked at $343K in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Summit Financial held 3,825 shares of Corcept Therapeutics worth $333K as of Q2 2026.
  • Corcept Therapeutics was a new Summit Financial position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Summit Financial's portfolio in Q2 2026, its #1267 holding.
  • Summit Financial first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Summit Financial's Corcept Therapeutics position peaked at $343K in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Summit Financial's 13F filing for Q2 2026, filed 12 Aug 2026.